Related Experiment Video
Updated: Dec 20, 2025
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.6K
Optimising Radium 223 Therapy for Metastatic Castration-Resistant Prostate Cancer -5-year Real-World Outcome:
X Y Jiang1, S Atkinson2, R Pearson3
1Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|May 26, 2020
Summary
Radium 223 (Ra-223) improves quality of life and palliates pain in men with metastatic castration-resistant prostate cancer. Real-world data shows chemotherapy-naïve patients have better survival, and bone health monitoring is crucial.
Area of Science:
- Oncology
- Radiopharmaceuticals
- Prostate Cancer Research
Background:
- Metastatic castration-resistant prostate cancer (mCRPC) presents significant treatment challenges.
- Radium 223 (Ra-223) dichloride is an alpha-particle emitting radiopharmaceutical used for mCRPC.
- Real-world evidence on Ra-223's effectiveness and impact on quality of life (QoL) is increasingly important.
Purpose of the Study:
- To evaluate real-world QoL and survival outcomes of Ra-223 treatment in mCRPC patients in the UK.
- To analyze the impact of treatment sequencing on outcomes.
- To share 5-year experience for optimizing Ra-223 therapy.
Main Methods:
- Prospective service evaluation of 228 mCRPC patients treated with Ra-223 between 2014-2018.
- Collection of demographics, clinical data, and QoL using FACT-P questionnaires.
- Analysis of survival data based on prior treatments (chemotherapy, enzalutamide, abiraterone/prednisolone).
Main Results:
- Overall median survival was 11.1 months.
- Chemotherapy-naïve patients showed significantly better survival (12.3 months) than post-chemotherapy patients (8.1 months).
- QoL improved for pain in 54% of patients; overall QoL scores showed a similar trend. Fracture rate was 24% in the post-abiraterone/prednisolone group.
Conclusions:
- Ra-223 effectively palliates pain and improves QoL in real-world mCRPC settings.
- Chemotherapy-naïve status is associated with better survival outcomes.
- Bone health assessment and protection should be integrated into standard care for patients receiving Ra-223.
